11 DRESS Syndrome

Total Page:16

File Type:pdf, Size:1020Kb

11 DRESS Syndrome PEDIATRIC PHARMACOTHERAPY A Monthly Newsletter for Health Care Professionals from the University of Virginia Children’s Hospital Volume 18 Number 11 November 2012 DRESS Syndrome: Examples from the Pediatric Literature Marcia L. Buck, Pharm.D., FCCP, FPPAG he acronym Drug Reaction with Diagnostic Criteria T Eosinophila and Systemic Symptoms Two groups have developed specific criteria for (DRESS) was first used by Bocquet and making the diagnosis of DRESS.4,6,7 The colleagues in 1996 to describe patients exhibiting RegiSCAR program was developed by an a drug-induced condition characterized by an international study group investigating severe extensive rash, fever, lymphadenopathy, cutaneous reactions (SCAR).7 To meet the hematologic abnormalities, hepatitis, and definition of DRESS, patients must have three of involvement of the kidneys, lungs, heart, or the four main RegiSCAR criteria: an acute rash, pancreas.1 The onset of symptoms is often fever above 38◦ C, lymphadenopathy at two sites, delayed, occurring 2-6 weeks after drug involvement of at least one internal organ, and initiation. DRESS syndrome shares many abnormalities in lymphocyte and eosinophil characteristics in common with anticonvulsant counts. Additional criteria include hospitalization hypersensitivity syndrome (AHS), also referred and that the reaction is suspected to be drug- to as drug-induced hypersensitivity syndrome related. (DIHS), and appears to represent a variation in presentation rather than a distinctly different A Japanese consensus group has developed a syndrome. The incidence of DRESS has been second set of criteria for DRESS.7 The diagnosis estimated to be between 1 in 1,000 and 1 in requires meeting seven of the nine criteria in this 10,000 drug exposures. It carries a mortality rate system or all of the first five: a maculopapular of 10-20%, with most fatalities the result of liver rash developing > 3 weeks after drug initiation, failure. Treatment consists of supportive clinical symptoms continuing > 2 weeks after therapy, corticosteroids, and antihistamines.2-4 stopping therapy, fever > 38◦ C, liver abnormalities (ALT > 100 IU/L) or other organ Proposed Mechanisms involvement, leukocytosis, atypical lymphocytes, The pathogenesis of DRESS syndrome is not yet eosinophilia, lymphadenopathy, or HHV-6 well understood. Although it is considered an reactivation. idiosyncratic reaction, three potential causative factors have been identified among multiple Drugs Associated with DRESS cases: 1) a defect in drug metabolism resulting in More than 50 drugs have been linked to DRESS the failure to eliminate toxic reactive syndrome. The drugs most often reported with intermediates, 2) reactivation of human DRESS include anticonvulsants (particularly herpesvirus 6 (HHV-6), human herpesvirus 7 those with aromatic structures), sulfa derivatives, (HHV-7), Epstein-Barr virus (EBV), or antidepressants, nonsteroidal anti-inflammatory cytomegalovirus (CMV), which may serve as a drugs, and antimicrobials (Table).2,3,8 trigger for the reaction, and 3) a genetic predisposition that alters immune response.1-4 Table. Drugs associated with DRESS in two or more cases Based on these factors, Moling and colleagues Abacavir Lamotrigine successfully treated an adult with sulfasalazine- Allopurinol Mexiletine related DRESS using a combination of Amitriptyline Minocycline prednisone, N-acetylcysteine to neutralize Captopril Nevirapine reactive metabolites and reduce oxidative stress, Carbamazepine Oxcarbazepine and valganciclovir to reduce the effects of HHV- Cefixime Phenobarbital 6 reactivation.5 Further work is needed to Celecoxib Phenytoin establish the efficacy of this novel combination Dapsone Sulfasalazine and determine its potential role in the Hydroxychloroquine Sulfamethoxazole management of DRESS syndrome. Ibuprofen Vancomycin Recent Pediatric Case Reports vesiculation and patchy exocytosis. A diagnosis of DRESS was made, phenytoin was stopped, Phenytoin and prednisolone was started at a dose of 1 Cases of both AHS and DRESS have been mg/kg/day. The patient’s symptoms resolved reported in children taking phenytoin. In 2009, within a week. Prednisolone was continued for 2 Armin and colleagues described two cases.9 The weeks, followed by a 4-week taper. first patient, a 7-year-old boy with a complex medical history including chronic renal failure, Deka and colleagues described a 10-year-old boy developed fever and a skin rash which persisted who developed a high fever, cough, respiratory despite a month of antibiotics. His symptoms distress, hoarseness, and a rash while taking progressed to include lymphadenopathies and clonazepam, gabapentin, and phenytoin.11 His arthralgia, along with a mild anemia, leukopenia, symptoms progressed to include oral mucosal and an elevated erythrocyte sedimentation rate ulceration, lymphadenopathy, periorbital and (ESR). His symptoms failed to improve after extremity edema, hepatomegaly, and rales. stopping the antibiotics. Upon detailed review of Laboratory values revealed eosinophilia and the patient’s history, it was discovered that he elevated serum transaminases. Antibiotic had started therapy with phenytoin 2 months treatment with amoxicillin-clavulanic acid and earlier. A diagnosis of AHS was made and the vancomycin failed to produce improvement. A phenytoin was discontinued. The fever and rash diagnosis of DRESS was made, phenytoin was resolved within one week. At follow-up 3 weeks discontinued, and steroid therapy was started. later, all symptoms had resolved and all Within 48 hours, the patient defervesced and his laboratory tests were approaching normal values. symptoms began to resolve. In the second case, a 5-year-old girl was admitted Carbamazepine and Oxcarbazepine with a history of fever, rash, and Buyuktiryaki and colleagues described DRESS lymphadenopathy for 2 weeks. She subsequently in an 8-year-old girl taking carbamazepine.12 developed hepatosplenomegaly and severe The patient initially presented to an emergency respiratory distress with a parahilar infiltrate. department with fever, lymphadenopathy, and a Laboratory values indicated leukocytosis, rash on her trunk. She was given amoxicillin- eosinophilia, thrombocytopenia, increased clavulanic acid, acetaminophen, and transaminase levels, and an increased ESR. hydroxyzine. Ten days later, she returned with After a patient history revealed the use of no improvement. A detailed medication history phenytoin for the previous 1.5 months, a revealed that the patient had been prescribed diagnosis of presumed DRESS was made and carbamazepine 5 weeks earlier. During her phenytoin was discontinued. Although hospitalization, she developed cervical administration of intravenous immune globulin lymphadenopathy, a desquamating rash on the early during her admission failed to produce face, trunk, and extremities, and improvement, treatment with methylprednisolone hepatosplenomegaly. Laboratory values at the time when phenytoin was stopped resulted included a leukocyte count of 6,200/μL with 22% in significant benefit. Her fever, rash, and eosinophils, 41% neutrophils, 29% lymphocytes, respiratory distress resolved within a week. and 7% monocytes. Serum transaminases were within the normal range, but γ-glutamyl Two more pediatric cases of phenytoin- transferase was elevated at 296 IU/L. Her C- associated DRESS were published earlier this reactive protein was 7.5 mg/dL (normal < 0.8 year. Gupta and colleagues described the case of mg/dL). Immunoglobulin and complement levels a 16-year-old boy in BMJ Case Reports.10 The were normal. Bone marrow aspiration revealed patient had been taking phenytoin 300 mg/day dysplastic changes with 24% eosinophils. and folic acid 5 mg/day for 6 weeks. He presented with a high-grade fever, jaundice, and After the patient failed to respond to antibiotics, an erythematous rash that had been present for 15 a hypersensitivity reaction to carbamazepine was days. The rash began as a maculopapular suspected. Skin biopsy revealed acanthosis, eruption, but progressed to an exfoliative parakeratosis, and spongiosis in the epidermis, dermatitis. Upon examination, he had edema, and eosinophilic infiltration in the generalized lymphadenopathy and tender dermis. After meeting the RegiSCAR criteria for hepatomegaly. Laboratory values included a DRESS, the patient’s carbamazepine was hemoglobin of 12 g/dL and a leukocyte count of replaced with levetiracetam and a short course of 15,700/mm3, with 15% eosinophils, 52% systemic corticosteroids and an antihistamine polymorphs, 28% lymphocytes, and 5% were started. Symptoms resolved within 4 monocytes. Serum transaminases were greater weeks. Six weeks after her recovery, the patient than 5 times the upper limit of normal, with a underwent patch testing to compare her reaction serum bilirubin of 7.6 mg/dL. A biopsy of the to carbamazepine, levetiracetam, and petroleum rash revealed spongiosis with intraepidermal as a control. Carbamazepine produced a positive response within 48 hours at both 5 and 10% for an upper respiratory tract infection.16 The concentrations. Levetiracetam and the control patient presented with a pruritic rash, fever, and produced no response. periorbital and perioral edema. She had been prescribed oral penicillin V for Oxcarbazepine, the keto homologue of tonsillopharyngitis 15 days earlier. After failing carbamazepine, has been linked to DRESS in a to improve, she was hospitalized and given IV single case report. In a 2004 issue of Archives of penicillin for 2 days, followed by ceftriaxone
Recommended publications
  • 35 Cyproterone Acetate and Ethinyl Estradiol Tablets 2 Mg/0
    PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PrCYESTRA®-35 cyproterone acetate and ethinyl estradiol tablets 2 mg/0.035 mg THERAPEUTIC CLASSIFICATION Acne Therapy Paladin Labs Inc. Date of Preparation: 100 Alexis Nihon Blvd, Suite 600 January 17, 2019 St-Laurent, Quebec H4M 2P2 Version: 6.0 Control # 223341 _____________________________________________________________________________________________ CYESTRA-35 Product Monograph Page 1 of 48 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION ....................................................................... 3 SUMMARY PRODUCT INFORMATION ............................................................................................. 3 INDICATION AND CLINICAL USE ..................................................................................................... 3 CONTRAINDICATIONS ........................................................................................................................ 3 WARNINGS AND PRECAUTIONS ....................................................................................................... 4 ADVERSE REACTIONS ....................................................................................................................... 13 DRUG INTERACTIONS ....................................................................................................................... 16 DOSAGE AND ADMINISTRATION ................................................................................................ 20 OVERDOSAGE ....................................................................................................................................
    [Show full text]
  • Revised 4/1/2021 GEORGIA MEDICAID FEE-FOR-SERVICE HIV
    GEORGIA MEDICAID FEE-FOR-SERVICE HIV-AIDS PA SUMMARY Preferred (may not be all inclusive) Non-Preferred Abacavir generic Abacavir/lamivudine/zidovudine generic Abacavir/lamivudine generic Aptivus (tipranavir) Complera (emtricitabine/rilpivirine/tenofovir disoproxil Atazanavir capsules generic fumarate) Atripla (efavirenz/emtricitabine/tenofovir disoproxil Crixivan (indinavir) fumarate) Biktarvy (bictegravir/emtricitabine/tenofovir Delstrigo (doravirine/lamivudine/tenofovir disoproxil alafenamide) fumarate) Cimduo (lamivudine/tenofovir disoproxil fumarate) Fuzeon (enfuvirtide) Descovy (emtricitabine/tenofovir alafenamide) Intelence (etravirine) Dovato Invirase (saquinavir) Edurant (rilpivirine)* Lexiva (fosamprenavir) Efavirenz tablets generic Nevirapine extended-release generic Emtriva (emtricitabine) Norvir Powder (ritonavir) Epivir solution (lamivudine) Pifeltro (doravirine) Evotaz (atazanavir/cobicistat)* Reyataz Powder (atazanavir) Genvoya (elvitegravir/cobicistat/emtricitabine/ Ritonavir tablets generic tenofovir alafenamide) Isentress and Isentress HD (raltegravir)* Rukobia (fostemsavir) Juluca (dolutegravir/rilpivirine) Selzentry (maraviroc) Kaletra (lopinavir/ritonavir) Stavudine generic^ Stribild (elvitegravir/cobicistat/emtricitabine/ tenofovir Lamivudine generic disoproxil fumarate) Symfi (efavirenz 600 mg/lamivudine/tenofovir Lamivudine/zidovudine generic disoproxil fumarate) Symfi Lo (efavirenz 400 mg/lamivudine/tenofovir Nevirapine immediate-release tablets generic disoproxil fumarate) Norvir (ritonavir) Temixys (lamivudine/tenofovir
    [Show full text]
  • Recommendations for the Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection Table of Contents Table 1
    Recommendations for the Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection Table of Contents Table 1. Outline of the Guidelines Development Process..........................................................................................................................1 Table 2. Rating Scheme for Recommendations........................................................................................................................................3 Table 3. Sample Schedule for Clinical and Laboratory Monitoring of Children Before and After Initiation of Combination Antiretroviral Therapy .................................................................................................................4 Table 4. Primary FDA-Approved Assays for Monitoring Viral Load D-8 Table 5. HIV Infection Stage Based on Age-Specific CD4 Count or Percentage ........................................................................................4 Table 6. HIV-Related Symptoms and Conditions ......................................................................................................................................5 Table 7. Antiretroviral Regimens Recommended for Initial Therapy for HIV Infection in Children ...........................................................................................................................................................................................7 Table 8. Advantages and Disadvantages of Antiretroviral Components Recommended for Initial Therapy in Children ............................................................................................................................................................10
    [Show full text]
  • Divestra Leaflet
    • Known or suspected estrogen-dependent neoplasia Drugs which may decrease the therapeutic effect of Cyproterone acetate+Ethinyl Pregnancy and Breastfeeding • Undiagnosed abnormal vaginal bleeding Combination of Cyproterone acetate and Ethinyl estradiol is contraindicated during estradiol and increase the incidence of breakthrough bleeding • Any ocular lesion arising from ophthalmic vascular disease, such as partial or complete pregnancy and breastfeeding. loss of vision or defect in visual fields Effects on ability to drive and use machines • Concomitant use with other Estrogen+Progestogen combinations or estrogens or Unknown progestogens alone • When pregnancy is suspected or diagnosed Adverse Reactions • Severe diabetes with vascular changes Common adverse reactions includes headaches, nausea, abdominal pain, weight gain, • A history of otosclerosis with deterioration during pregnancy depressed or altered mood and breast pain or tenderness. • Hypersensitivity to this drug or to any ingredient in the formulation or component of the Uncommon adverse reactions include vomiting, diarrhea, fluid retention and migraine. container. Overdose (Cyproterone acetate + Warnings and Precautions There is no antidote and treatment should be symptomatic. Ethinyl estradiol) Discontinue Cyproterone acetate+Ethinyl estradiol tablets at the earliest manifestation of the following: PHARMACOLOGICAL PROPERTIES • Thromboembolic and Cardiovascular Disorders such as thrombophlebitis, pulmonary Pharmacotherapeutic group: Sex hormones and modulators of the genital system, QUALITATIVE AND QUANTITATIVE COMPOSITION embolism, cerebrovascular disorders, myocardial ischemia, mesenteric thrombosis, and anti-androgens and estrogens. ATC code: G03HB01 Each film-coated tablet contains: retinal thrombosis. Cyproterone acetate (Ph.Eur.)………...2 mg • Conditions that predispose to Venous Stasis and to Vascular Thrombosis (eg. Mechanism of action Ethinyl estradiol (USP)……………...0.035 mg immobilization after accidents or confinement to bed during long-term illness).
    [Show full text]
  • Original Article Factors Influencing Efavirenz and Nevirapine Plasma Concentration: Effect of Ethnicity, Weight and Co-Medication
    Antiviral Therapy 13:675–685 Original article Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication Wolfgang Stöhr1, David Back 2, David Dunn1, Caroline Sabin3, Alan Winston4, Richard Gilson5, Deenan Pillay 6, Teresa Hill 3, Jonathan Ainsworth7, Anton Pozniak8, Clifford Leen9, Loveleen Bansi3, Martin Fisher10, Chloe Orkin11, Jane Anderson12, Margaret Johnson13, Phillippa Easterbrook14, Sara Gibbons2 and Saye Khoo2* on behalf of the Liverpool TDM Database and the UK CHIC Study 1MRC Clinical Trials Unit, London, UK 2University of Liverpool, Liverpool, UK 3Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK 4St. Mary’s Hospital, London, UK 5Mortimer Market Centre, Royal Free and University College Medical School (RFUCMS), London, UK 6Department of Infection, RFUCMS, Centre for Infection, Health Protection Agency, London, UK 7North Middlesex University Hospital, London, UK 8Chelsea and Westminster NHS Trust, London, UK 9University of Edinburgh, Western General Hospital, Edinburgh, UK 10Brighton and Sussex University Hospitals NHS Trust, Sussex, UK 11Barts and The London NHS Trust, London, UK 12Homerton Hospital, London, UK 13Royal Free NHS Trust and RFUCMS, London, UK 14King’s College Hospital, London, UK *Corresponding author: E-mail: [email protected] Background: The aim of this study was to examine and zidovudine (25% lower; P=0.010). Notably, without factors influencing plasma concentration of efavirenz and adjustment for other factors, patients on rifampicin had nevirapine. 48% higher efavirenz concentration, as these patients Methods: Data from the Liverpool Therapeutic Drug Mon- were mostly black and on 800 mg/day. For nevirapine the itoring (TDM) registry were linked with the UK Collabora- predictors were black ethnicity (39% higher; P=0.002), tive HIV Cohort (CHIC) Study.
    [Show full text]
  • Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis
    Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Division of Tuberculosis Elimination Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis Centers for Disease Control and Prevention Office of Infectious Diseases National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Division of Tuberculosis Elimination June 2013 This document is accessible online at http://www.cdc.gov/tb/TB_HIV_Drugs/default.htm Suggested citation: CDC. Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis [online]. 2013. Available from URL: http://www.cdc.gov/tb/TB_HIV_Drugs/default.htm Table of Contents Introduction 1 Methodology for Preparation of these Guidelines 2 The Role of Rifamycins in Tuberculosis Treatment 4 Managing Drug Interactions with Antivirals and Rifampin 5 Managing Drug Interactions with Antivirals and Rifabutin 9 Treatment of Latent TB Infection with Rifampin or Rifapentine 10 Treating Pregnant Women with Tuberculosis and HIV Co-infection 10 Treating Children with HIV-associated Tuberculosis 12 Co-treatment of Multidrug-resistant Tuberculosis and HIV 14 Limitations of these Guidelines 14 HIV-TB Drug Interaction Guideline Development Group 15 References 17 Table 1a. Recommendations for regimens for the concomitant treatment of tuberculosis and HIV infection in adults 21 Table 1b. Recommendations for regimens for the concomitant treatment of tuberculosis and HIV infection in children 22 Table 2a. Recommendations for co-administering antiretroviral drugs with RIFAMPIN in adults 23 Table 2b. Recommendations for co-administering antiretroviral drugs with RIFAMPIN in children 25 Table 3. Recommendations for co-administering antiretroviral drugs with RIFABUTIN in adults 26 ii Introduction Worldwide, tuberculosis is the most common serious opportunistic infection among people with HIV infection.
    [Show full text]
  • Fatal Nevirapine-Induced Stevens- Johnson Syndrome with HIV-Associated Mania
    CASE REPORT Fatal nevirapine-induced Stevens- Johnson syndrome with HIV-associated mania Z Zingela,1 MB ChB, MMed (Psych), FC Psych (SA); A Bronkhorst,1 MB ChB, DMH (SA); W M Qwesha,2 MB ChB; B P Magigaba,2 MB ChB, FC Derm (SA) 1 Department of Psychiatry, Port Elizabeth Hospital Complex, Walter Sisulu University, South Africa 2 Department of Dermatology, Port Elizabeth Hospital Complex, Walter Sisulu University, South Africa Corresponding author: Z Zingela ([email protected]) Mania with psychotic features is one of the common presenting clusters of psychiatric symptoms in HIV-infected patients. Commonly, patients with HIV-associated mania receive antiretroviral treatment, mood stabilisers and antipsychotics. This case of Stevens-Johnson syndrome highlights the dilemmas and complications that may arise when prescribing multiple medications in HIV-associated psychiatric disorders. S Afr J HIV Med 2014;15(2):65-66. DOI:10.7196/SAJHIVMED.1011 HIV enters the central nervous system early status and CD4+ count, ethnic background, age and gender. in the course of HIV infection and causes a Affected individuals with SJS/TEN are genetically predisposed range of neuropsychiatric complications, inclu- to developing severe cutaneous reactions based on the major ding HIV encephalopathy, depression, ma- histocompatibility complex molecules on their leukocyte cell [1] [10] nia, cognitive disorders and frank demen tia. surface. A study in Taiwan showed that 100% of Han Chinese Mania is one of the most common psychiatric presentations in patients who developed SJS in response to carbamazepine HIV-infected patients and requires antiretroviral therapy (ART), had an HLA B*1502 allele.[11] Comorbidity of SJS/TEN and mood stabilisers and antipsychotics to increase patient quality of HIV is posing a challenge in sub-Saharan Africa due to the life and decrease mortality.[1-3] ART may also protect from further high prevalence of HIV.
    [Show full text]
  • (Nevirapine) Oral Suspension
    NDA 20-636 NDA 20-933 Page 3 Viramune® (nevirapine) Tablets Viramune® (nevirapine) Oral Suspension Rx only WARNING Severe, life-threatening, and in some cases fatal hepatotoxicity, including fulminant and cholestatic hepatitis, hepatic necrosis and hepatic failure, has been reported in patients treated with VIRAMUNEâ. In some cases, patients presented with non-specific prodromal signs or symptoms of hepatitis and progressed to hepatic failure. Patients with signs or symptoms of hepatitis must seek medical evaluation immediately and should be advised to discontinue VIRAMUNE. (See WARNINGS) Severe, life-threatening skin reactions, including fatal cases, have occurred in patients treated with VIRAMUNE. These have included cases of Stevens-Johnson syndrome, toxic epidermal necrolysis, and hypersensitivity reactions characterized by rash, constitutional findings, and organ dysfunction. Patients developing signs or symptoms of severe skin reactions or hypersensitivity reactions must discontinue VIRAMUNE as soon as possible. (See WARNINGS) It is essential that patients be monitored intensively during the first 12-16 weeks of therapy with VIRAMUNE to detect potentially life-threatening hepatotoxicity or skin reactions. However, the risk continues past this period and monitoring should continue at frequent intervals. VIRAMUNE should not be restarted following severe hepatic, skin or hypersensitivity reactions. In addition, the 14-day lead-in period with VIRAMUNE 200 mg daily dosing must be strictly followed. (See WARNINGS) DESCRIPTION VIRAMUNE IS THE BRAND NAME FOR NEVIRAPINE (NVP), A NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR WITH ACTIVITY AGAINST HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1). NEVIRAPINE IS STRUCTURALLY A MEMBER OF THE DIPYRIDODIAZEPINONE CHEMICAL CLASS OF COMPOUNDS. VIRAMUNE TABLETS ARE FOR ORAL ADMINISTRATION. EACH TABLET CONTAINS 200 MG OF NEVIRAPINE AND THE INACTIVE INGREDIENTS MICROCRYSTALLINE CELLULOSE, LACTOSE MONOHYDRATE, POVIDONE, SODIUM STARCH GLYCOLATE, COLLOIDAL SILICON DIOXIDE AND MAGNESIUM STEARATE.
    [Show full text]
  • HIV/AIDS Formulary Instructions
    2022 S a fe H a r b o r G u i d e l i n e s fo r H I V/A I D S D r u g s PPACA Guidance to Insurers: At least one form of each drug must be offered if no specific dosage is listed below. Any additional anti-retroviral medications beyond those listed should be tiered according to cost, and not according to the medical diagnosis or condition being treated. Preauthorization should not be required except in cases of suspected fraud. Drug quantities should never be limited to less than a thirty (30) day supply and any refills authorized by the treating physician. Step therapy should not be required for the administration of any of these drugs. Compliance with the safe harbor guidelines is not mandatory. However, the Office is prohibited from certifying a plan to be included on the Federal Health Insurance Marketplace if the Office knows that the plan employs a drug formulary discriminatory in benefit design, benefit implementation or medical management techniques. Additionally, the Office will disapprove any plan it finds violates Sections 627.429, 641.3007, or 641.31(3)(c)6., Florida Statutes. Lowest Generic Tier Exclusive of tiers comprised solely of preventive and value based generics Maximum cost sharing per 30-day supply: $40 • abacavir (20 mg/mL oral solution, 300 mg oral tablet) • abacavir/lamivudine (600 mg/300 mg oral tablet) • abacavir/lamivudine/zidovudine (300 mg/150 mg/300 mg oral tablet) • atazanavir (150 mg, 200 mg, 300 mg oral capsule) • didanosine (125 mg, 200 mg, 250 mg, 400 mg delayed release oral capsule) • efavirenz (50
    [Show full text]
  • 2021 Formulary List of Covered Prescription Drugs
    2021 Formulary List of covered prescription drugs This drug list applies to all Individual HMO products and the following Small Group HMO products: Sharp Platinum 90 Performance HMO, Sharp Platinum 90 Performance HMO AI-AN, Sharp Platinum 90 Premier HMO, Sharp Platinum 90 Premier HMO AI-AN, Sharp Gold 80 Performance HMO, Sharp Gold 80 Performance HMO AI-AN, Sharp Gold 80 Premier HMO, Sharp Gold 80 Premier HMO AI-AN, Sharp Silver 70 Performance HMO, Sharp Silver 70 Performance HMO AI-AN, Sharp Silver 70 Premier HMO, Sharp Silver 70 Premier HMO AI-AN, Sharp Silver 73 Performance HMO, Sharp Silver 73 Premier HMO, Sharp Silver 87 Performance HMO, Sharp Silver 87 Premier HMO, Sharp Silver 94 Performance HMO, Sharp Silver 94 Premier HMO, Sharp Bronze 60 Performance HMO, Sharp Bronze 60 Performance HMO AI-AN, Sharp Bronze 60 Premier HDHP HMO, Sharp Bronze 60 Premier HDHP HMO AI-AN, Sharp Minimum Coverage Performance HMO, Sharp $0 Cost Share Performance HMO AI-AN, Sharp $0 Cost Share Premier HMO AI-AN, Sharp Silver 70 Off Exchange Performance HMO, Sharp Silver 70 Off Exchange Premier HMO, Sharp Performance Platinum 90 HMO 0/15 + Child Dental, Sharp Premier Platinum 90 HMO 0/20 + Child Dental, Sharp Performance Gold 80 HMO 350 /25 + Child Dental, Sharp Premier Gold 80 HMO 250/35 + Child Dental, Sharp Performance Silver 70 HMO 2250/50 + Child Dental, Sharp Premier Silver 70 HMO 2250/55 + Child Dental, Sharp Premier Silver 70 HDHP HMO 2500/20% + Child Dental, Sharp Performance Bronze 60 HMO 6300/65 + Child Dental, Sharp Premier Bronze 60 HDHP HMO
    [Show full text]
  • Trial in Youngest Group Points to HIV Treatment Overhaul
    NEWS Trial in youngest group points to HIV treatment overhaul BOSTON — By some estimates, around 1,800 children, mostly newborns, become infected with HIV each day. But even though the stakes are high, the most commonly used strategy to combat the deadly virus among infected children in resource-limited countries may need a massive overhaul. According to data presented here last month at the Conference on Retroviruses and Opportunistic Infections, babies born with HIV should immediately start receiving antiretroviral drugs known as protease inhibitors, not the reverse transcriptase inhibitor widely used throughout the developing world. “We have created a bit of a stir at the guideline level moving forward,” says Paul Palumbo, a pediatrician at Dartmouth Medical School in Hanover, New Hampshire. “We need to Design Pics/Newscom move into considerations of using [protease Newborn notions: Experts are rethinking HIV treatments for infants. inhibitors] as a first-line therapy.” The reverse transcriptase–blocking drug the age of three at ten study sites across sub- in Bethesda, Maryland and a project officer for nevirapine, marketed as Viramune by the Saharan Africa and India. the IMPAACT group. Mofenson notes that German company Boehringer-Ingelheim, is the “Kaletra is really the drug that you should infants tend to have elevated viral counts and cornerstone of both preventing mother-to-child use to treat young children regardless of their highly compromised immune systems, “so transmission of HIV and treating infections in exposure to nevirapine,” says Marc Lallemant, they’re much less able to control the virus than affected infants in the third world, where the an epidemiologist at the Institute for Research adults or older children.” vast majority of the world’s 2.1 million HIV- and Development in Marseilles, France who Doctors are now calling for new guidelines positive children live.
    [Show full text]
  • Clinically Relevant Drug Interactions with Antiepileptic Drugs
    British Journal of Clinical Pharmacology DOI:10.1111/j.1365-2125.2005.02529.x Clinically relevant drug interactions with antiepileptic drugs Emilio Perucca Institute of Neurology IRCCS C. Mondino Foundation, Pavia, and Clinical Pharmacology Unit, Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy Correspondence Some patients with difficult-to-treat epilepsy benefit from combination therapy with Emilio Perucca MD, PhD, Clinical two or more antiepileptic drugs (AEDs). Additionally, virtually all epilepsy patients will Pharmacology Unit, Department of receive, at some time in their lives, other medications for the management of Internal Medicine and Therapeutics, associated conditions. In these situations, clinically important drug interactions may University of Pavia, Piazza Botta 10, occur. Carbamazepine, phenytoin, phenobarbital and primidone induce many cyto- 27100 Pavia, Italy. chrome P450 (CYP) and glucuronyl transferase (GT) enzymes, and can reduce Tel: + 390 3 8298 6360 drastically the serum concentration of associated drugs which are substrates of the Fax: + 390 3 8222 741 same enzymes. Examples of agents whose serum levels are decreased markedly by E-mail: [email protected] enzyme-inducing AEDs, include lamotrigine, tiagabine, several steroidal drugs, cyclosporin A, oral anticoagulants and many cardiovascular, antineoplastic and psy- chotropic drugs. Valproic acid is not enzyme inducer, but it may cause clinically relevant drug interactions by inhibiting the metabolism of selected substrates, most Keywords notably phenobarbital and lamotrigine. Compared with older generation agents, most antiepileptic drugs, drug interactions, of the recently developed AEDs are less likely to induce or inhibit the activity of CYP enzyme induction, enzyme inhibition, or GT enzymes. However, they may be a target for metabolically mediated drug epilepsy, review interactions, and oxcarbazepine, lamotrigine, felbamate and, at high dosages, topira- mate may stimulate the metabolism of oral contraceptive steroids.
    [Show full text]